Association between HIV Serostatus and premalignant cervical lesions among women attending a cervical cancer screening clinic at a tertiary care facility in southwestern Uganda: a comparative cross-sectional study.
Humans
Female
Adult
Cross-Sectional Studies
Uganda
/ epidemiology
Uterine Cervical Neoplasms
/ epidemiology
Middle Aged
Young Adult
Early Detection of Cancer
/ methods
HIV Infections
/ complications
Prevalence
Precancerous Conditions
/ epidemiology
Aged
Papanicolaou Test
/ statistics & numerical data
Tertiary Care Centers
/ statistics & numerical data
HIV Seropositivity
/ epidemiology
Uterine Cervical Dysplasia
/ epidemiology
Papillomavirus Infections
/ epidemiology
Vaginal Smears
/ statistics & numerical data
HIV
High-grade squamous intraepithelial lesion
Low-grade squamous intraepithelial lesion
Papanicolaou smears
Uganda
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
27 Apr 2024
27 Apr 2024
Historique:
received:
10
02
2023
accepted:
23
04
2024
medline:
28
4
2024
pubmed:
28
4
2024
entrez:
27
4
2024
Statut:
epublish
Résumé
Uganda has approximately 1.2 million people aged 15-64 years living with human immunodeficiency virus (HIV). Previous studies have shown a higher prevalence of premalignant cervical lesions among HIV-positive women than among HIV-negative women. Additionally, HIV-infected women are more likely to have human papilloma virus (HPV) infection progress to cancer than women not infected with HIV. We determined the prevalence of premalignant cervical lesions and their association with HIV infection among women attending a cervical cancer screening clinic at Mbarara Regional Referral Hospital (MRRH) in southwestern Uganda. We conducted a comparative cross-sectional study of 210 women aged 22-65 years living with HIV and 210 women not living with HIV who were systematically enrolled from March 2022 to May 2022. Participants were subjected to a structured interviewer-administered questionnaire to obtain their demographic and clinical data. Additionally, Papanicolaou smears were obtained for microscopy to observe premalignant cervical lesions. Multivariate logistic regression was performed to determine the association between HIV status and premalignant cervical lesions. The overall prevalence of premalignant cervical lesions in the study population was 17% (n = 72; 95% C.I: 14.1-21.4), with 23% (n = 47; 95% C.I: 17.8-29.5) in women living with HIV and 12% (n = 25; 95% C.I: 8.2-17.1) in women not living with HIV (p < 0.003). The most common premalignant cervical lesions identified were low-grade squamous intraepithelial lesions (LSIL) in both women living with HIV (74.5%; n = 35) and women not living with HIV (80%; n = 20). HIV infection was significantly associated with premalignant lesions (aOR: 2.37, 95% CI: 1.27-4.42; p = 0.007). Premalignant cervical lesions, particularly LSILs, were more common in HIV-positive women than in HIV-negative women, highlighting the need to strengthen the integration of cervical cancer prevention strategies into HIV care programs.
Sections du résumé
BACKGROUND
BACKGROUND
Uganda has approximately 1.2 million people aged 15-64 years living with human immunodeficiency virus (HIV). Previous studies have shown a higher prevalence of premalignant cervical lesions among HIV-positive women than among HIV-negative women. Additionally, HIV-infected women are more likely to have human papilloma virus (HPV) infection progress to cancer than women not infected with HIV. We determined the prevalence of premalignant cervical lesions and their association with HIV infection among women attending a cervical cancer screening clinic at Mbarara Regional Referral Hospital (MRRH) in southwestern Uganda.
METHODS
METHODS
We conducted a comparative cross-sectional study of 210 women aged 22-65 years living with HIV and 210 women not living with HIV who were systematically enrolled from March 2022 to May 2022. Participants were subjected to a structured interviewer-administered questionnaire to obtain their demographic and clinical data. Additionally, Papanicolaou smears were obtained for microscopy to observe premalignant cervical lesions. Multivariate logistic regression was performed to determine the association between HIV status and premalignant cervical lesions.
RESULTS
RESULTS
The overall prevalence of premalignant cervical lesions in the study population was 17% (n = 72; 95% C.I: 14.1-21.4), with 23% (n = 47; 95% C.I: 17.8-29.5) in women living with HIV and 12% (n = 25; 95% C.I: 8.2-17.1) in women not living with HIV (p < 0.003). The most common premalignant cervical lesions identified were low-grade squamous intraepithelial lesions (LSIL) in both women living with HIV (74.5%; n = 35) and women not living with HIV (80%; n = 20). HIV infection was significantly associated with premalignant lesions (aOR: 2.37, 95% CI: 1.27-4.42; p = 0.007).
CONCLUSION
CONCLUSIONS
Premalignant cervical lesions, particularly LSILs, were more common in HIV-positive women than in HIV-negative women, highlighting the need to strengthen the integration of cervical cancer prevention strategies into HIV care programs.
Identifiants
pubmed: 38678278
doi: 10.1186/s12905-024-03108-w
pii: 10.1186/s12905-024-03108-w
doi:
Types de publication
Journal Article
Comparative Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
266Informations de copyright
© 2024. The Author(s).
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.
doi: 10.3322/caac.21492
Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global Cancer in women: Burden and TrendsGlobal Cancer in women: Burden and Trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444–57.
doi: 10.1158/1055-9965.EPI-16-0858
pubmed: 28223433
Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.
doi: 10.1093/annonc/mdr015
pubmed: 21471563
Parkin D, Ferlay J, Hamdi-Cherif M, Sitas F, Thomas J, Wabinga H, et al. Cancer Afr Epidemiol Prev. 2003;4:268–76.
Anorlu RI. Cervical cancer: the sub-saharan African perspective. Reprod Health Matters. 2008;16(32):41–9.
doi: 10.1016/S0968-8080(08)32415-X
pubmed: 19027621
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health. 2020;8(2):e191–203.
doi: 10.1016/S2214-109X(19)30482-6
pubmed: 31812369
Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S et al. Human papillomavirus and related diseases in the world. Summary Rep. 2015;20140822.
Mulumba R, Lule H, Atuhaire C, Bonet I, Diaz AA. Scholars J Appl Med Sci (SJAMS) ISSN 2320–6691 (Online). 2018.
Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30:F88–99.
doi: 10.1016/j.vaccine.2012.06.095
pubmed: 23199969
WHO. Comprehensive cervical cancer control: a guide to essential practice. World Health Organization; 2006.
Nayar R, Wilbur DC. The Bethesda system for reporting cervical cytology: definitions, criteria, and explanatory notes. Springer; 2015.
Köse FM, Naki MM. Cervical premalignant lesions and their management. J Turkish German Gynecol Association. 2014;15(2):109.
doi: 10.5152/jtgga.2014.29795
Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114–9.
doi: 10.1001/jama.287.16.2114
pubmed: 11966386
Zhang H-Y, Tiggelaar SM, Sahasrabuddhe VV, Smith JS, Jiang C-Q, Mei R-B, et al. HPV prevalence and cervical intraepithelial neoplasia among HIV-infected women in Yunnan Province, China: a pilot study. Asian Pac J cancer Prevention: APJCP. 2012;13(1):91.
doi: 10.7314/APJCP.2012.13.1.091
Adjorlolo-Johnson G, Unger ER, Boni-Ouattara E, Touré-Coulibaly K, Maurice C, Vernon SD, et al. Assessing the relationship between HIV infection and cervical cancer in Cote d’Ivoire: a case-control study. BMC Infect Dis. 2010;10(1):1–8.
doi: 10.1186/1471-2334-10-242
Nweke I, Nwadike V, Kalu I, Ojide K. Human papilloma virus and cervical neoplasia in HIV positive women: a non systematic review. Afr J Microbiol Res. 2014;8(22):2193–201.
doi: 10.5897/AJMR2014.6649
Jolly PE, Mthethwa-Hleta S, Padilla LA, Pettis J, Winston S, Akinyemiju TF, et al. Screening, prevalence, and risk factors for cervical lesions among HIV positive and HIV negative women in Swaziland. BMC Public Health. 2017;17(1):1–8.
doi: 10.1186/s12889-017-4120-3
Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus–positive women. J Natl Cancer Inst. 2005;97(8):577–86.
doi: 10.1093/jnci/dji073
pubmed: 15840880
Whitham HK, Hawes SE, Chu H, Oakes JM, Lifson AR, Kiviat NB, et al. A comparison of the natural history of HPV infection and cervical abnormalities among HIV-positive and HIV-negative women in Senegal, Africa. Cancer Epidemiol Prev Biomarkers. 2017;26(6):886–94.
doi: 10.1158/1055-9965.EPI-16-0700
Memiah P, Makokha V, Mbuthia W, Kiiru GW, Agbor S, Odhiambo F, et al. Epidemiology of cervical squamous intraepithelial lesions in HIV infected women in Kenya: a cross-sectional study. Afr J Reprod Health. 2015;19(1):133–9.
pubmed: 26103703
Peter Memiah WM. 2 grace Kiiru,2 Solomon Agbor,1 Francesca Odhiambo,3 Sylvia Prevalence and Risk factors Associated with Precancerous Cervical Cancer lesions among HIV-Infected women in Resource-Limited Settings 2012.
Clarke B, Chetty R. Postmodern cancer: the role of human immunodeficiency virus in uterine cervical cancer. Mol Pathol. 2002;55(1):19.
doi: 10.1136/mp.55.1.19
pubmed: 11836442
pmcid: 1187141
Yang L, Morris GF, Lockyer JM, Lu M, Wang Z, Morris CB. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat. Virology. 1997;235(1):48–64.
doi: 10.1006/viro.1997.8672
pubmed: 9300036
Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P, Qiao Y-l, et al. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(1):e45–58.
doi: 10.1016/S2352-3018(17)30149-2
pubmed: 29107561
Taye BT, Mihret MS, Muche HA. Risk factors of precancerous cervical lesions: the role of women’s socio-demographic, sexual behavior and body mass index in Amhara region referral hospitals; case-control study. PLoS ONE. 2021;16(3):e0249218.
doi: 10.1371/journal.pone.0249218
pubmed: 33770125
pmcid: 7997028
Nkfusai NC, Mubah TM, Yankam BM, Tambe TA, Cumber SN. Prevalence of precancerous cervical lesions in women attending Mezam Polyclinic Bamenda, Cameroon. Pan Afr Med J. 2019;32.
Kassa RT. Risk factors associated with precancerous cervical lesion among women screened at Marie Stops Ethiopia, Adama town, Ethiopia 2017: a case control study. BMC Res Notes. 2018;11(1):1–5.
doi: 10.1186/s13104-018-3244-6
Ibrahim A, Rasch V, Pukkala E, Aro AR. Cervical cancer risk factors and feasibility of visual inspection with acetic acid screening in Sudan. Int J Women’s Health. 2011;3:117.
doi: 10.2147/IJWH.S14189
MOH. THE 2020 UGANDA POPULATION-BASED HIV IMPACT ASSESSMENT. 2022.
MRRH. Cervical cancer register. [Hospital records]. In press 2020.
MoH. Strategic plan for cervical cancer prevention and control in Uganda 2010–2014. Ministry of Health Kampala; 2010. p. 70.
Wang H, Chow SC. Sample size calculation for comparing proportions. Wiley Encyclopedia Clin Trials. 2007;10:9781118445112.
Dim C, Ezegwui H, Ikeme A, Nwagha U, Onyedum C. Prevalence of cervical squamous intraepithelial lesions among HIV-positive women in Enugu, South-eastern Nigeria. J Obstet Gynaecol. 2011;31(8):759–62.
doi: 10.3109/01443615.2011.598967
pubmed: 22085071
Alrajjal A, Pansare V, Choudhury MSR, Khan MYA, Shidham VB. Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System. CytoJournal. 2021;18.
MOH. National HIV Testing Services Policy and Implementation Guidelines Uganda. Ministry of Health Kampala, Uganda; 2016.
Getinet M, Gelaw B, Sisay A, Mahmoud EA, Assefa A. Prevalence and predictors of pap smear cervical epithelial cell abnormality among HIV-positive and negative women attending gynecological examination in cervical cancer screening center at Debre Markos referral hospital, East Gojjam, Northwest Ethiopia. BMC Clin Pathol. 2015;15(1):1–10.
doi: 10.1186/s12907-015-0016-2
Aynalem BY, Anteneh KT, Enyew MM. Utilization of cervical cancer screening and associated factors among women in Debremarkos town, Amhara region, Northwest Ethiopia: Community based cross-sectional study. PLoS ONE. 2020;15(4):e0231307.
doi: 10.1371/journal.pone.0231307
pubmed: 32255807
pmcid: 7138328
De Lemos PAP, García-Zapata MTA, Tavares SBN. Cervical cytopathology in a population of HIV-positive and HIV-negative women. Journal of tropical medicine. 2012;2012.
Lawal I, Agida TE, Offiong RA, Oluwole PO. Cervical cytology among HIV positive and HIV negative women in a tertiary hospital in North Central Nigeria: a comparative study. Annals of Medical and Health Sciences Research; 2017.
Chambuso RS, Shadrack S, Lidenge SJ, Mwakibete N, Medeiros RM. Influence of HIV/AIDS on cervical cancer: a retrospective study from Tanzania. J Global Oncol. 2017;3(1):72–8.
doi: 10.1200/JGO.2015.002964
Nakisige C, Schwartz M, Ndira AO. Cervical cancer screening and treatment in Uganda. Gynecologic Oncol Rep. 2017;20:37–40.
doi: 10.1016/j.gore.2017.01.009